What if researchers could create a detailed map of the human brain, cell by cell, showing which genes are active, how cells function and how those patterns change across a lifetime and in disease?
A new collection of studies is helping researchers build that picture in unprecedented detail.
Researchers with the PsychAD Consortium have created the largest single-cell map to date of gene activity in the human prefrontal cortex, a region involved in memory, decision-making and other complex functions. The resource includes more than 6 million individual cells from brain tissue donated by nearly 1,500 people, ranging in age from infancy to more than 100 years old.
The donors included people without neurological disease as well as people with Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, vascular dementia and other neurological or psychiatric conditions.
For Alzheimer’s researchers, the value of this work is not that it provides one new answer. It gives scientists a much more detailed way to ask questions about how disease develops and why some brain cells may be more vulnerable than others.
Why Look at Individual Cells?
The brain contains many different types of cells, and they perform very different jobs.
Neurons carry information. Other cells support and protect neurons, regulate immune responses or help maintain the brain’s blood vessels and surrounding environment.
Traditional studies of brain tissue can tell researchers which genes are active overall. But when many different cell types are analyzed together, important changes occurring in one particular type of cell can be difficult to detect.
The approach used in these studies, called single-nucleus RNA sequencing, allows researchers to examine gene activity at the level of individual cells.
That matters because Alzheimer’s disease does not affect every cell in the brain in the same way.
Alzheimer’s Is Not Simply Normal Aging Happening Faster
One particularly interesting finding is the distinction researchers observed between changes associated with normal aging and those associated with Alzheimer’s disease.
Some changes in gene activity occur as part of aging. But when researchers compared normal aging with Alzheimer’s disease, they identified patterns that appeared to be specific to the disease rather than simply an extension of getting older.
They observed changes in particular types of neurons as Alzheimer’s pathology increased, as well as changes involving immune cells and cells associated with the brain’s blood vessels.
The findings reinforce an important idea in Alzheimer’s research: the disease involves more than neurons alone.
Changes in immune function, blood vessels and the interactions among different types of brain cells may all play a role in how Alzheimer’s develops and progresses.
Why Does That Matter?
One of the major challenges in Alzheimer’s research is understanding why some cells become vulnerable while others remain relatively resilient.
If researchers can identify the molecular changes occurring in vulnerable cells, they may eventually uncover biological pathways that could become targets for future treatments.
Large datasets like this also allow scientists to compare diseases that can share symptoms or occur together, including Alzheimer’s disease, Parkinson’s disease, Lewy body dementia and vascular dementia.
Those comparisons may help researchers identify changes that are shared across several disorders as well as those that are more specific to one disease.
But these possibilities remain future goals.
This research does not provide a new diagnostic test or treatment for Alzheimer’s disease today. Instead, it provides a much more detailed map of the biology researchers are trying to understand.
A Resource Other Scientists Can Build Upon
The scale of this project is also important.
With data from nearly 1,500 donors and more than 6 million individual cells, researchers can examine biological differences between people in ways that were difficult with smaller studies.
The data are also being made available to other scientists, allowing researchers around the world to ask additional questions about genes, cell types and biological pathways.
That means the value of the project may extend well beyond the findings reported in these initial studies.
In that sense, the atlas is not simply the conclusion of a study. It is a new research tool.
What UCI MIND Researchers Are Asking Next
These findings connect directly to research underway at UCI MIND.
Vivek Swarup, PhD, Professor of Neurobiology and Behavior, studies why some brains appear more vulnerable to Alzheimer’s disease while others remain remarkably resilient. His laboratory examines how genes, gene activity and the interactions among different types of brain cells may influence the course of disease.
One question his team is pursuing is particularly important: Why does the amount of Alzheimer’s pathology in the brain not always predict how well a person thinks?
UCI’s 90+ Study offers a unique opportunity to explore that question. Co-founded by Claudia Kawas, MD, and María Corrada, ScD, the study has followed adults age 90 and older for more than two decades through repeated cognitive and neurological assessments.
Some participants remain cognitively intact despite substantial amyloid and tau pathology, while others develop dementia with comparatively less of the classical Alzheimer’s pathology. Researchers are using advanced techniques that allow them to study gene activity, genetics and the location of molecular changes within the brain to better understand what may contribute to resilience or vulnerability. Dr. Corrada is a co-investigator on this work, helping connect the molecular findings with the participants’ long-term clinical and pathological information.
Researchers are also asking where these molecular differences occur.
Finding a biological signal is one thing. Knowing whether it appears within a particular layer of the cortex, in white matter or near an Alzheimer’s plaque may provide additional clues about what that signal means.
A related UCI MIND project is examining these questions in adults with Down syndrome. Because people with Down syndrome have an extra copy of chromosome 21, which includes the APP gene, nearly all develop Alzheimer’s-related brain changes by around age 40. However, the timing of cognitive decline varies considerably from one person to another.
UCI researchers including Elizabeth Head, PhD, and Dr. Swarup are studying how inflammation, changes in white matter, communication between brain cells and other biological processes may contribute either to disease progression or to resilience.
Together, these studies are shifting part of the research question from what goes wrong in an Alzheimer’s brain to what allows some brains to keep working despite disease.
A resource like the new brain atlas can help identify the cell types and biological processes that change with aging and Alzheimer’s disease. Studies of well-characterized groups, including people in their 90s and people with Down syndrome, can then help researchers determine which of those changes may contribute to vulnerability, which may be responses to disease, and which may represent protective mechanisms.
That distinction could eventually matter for treatment. The goal is not only to reduce Alzheimer’s pathology, but also to better understand how the brain may withstand its effects.
Brain Donation Makes Research Like This Possible
There is another important part of this story.
This work was only possible because people participated in research and ultimately donated brain tissue for scientific study.
Brain donation allows researchers to compare what was known about an individual during life with the biological changes observed in the brain after death. When someone has participated in a study for many years, that connection can be especially valuable.
At UCI MIND, longitudinal research participants help scientists study how memory and thinking change over time, how biomarkers evolve and why some people develop Alzheimer’s disease while others do not. With participants’ and families’ permission, brain donation can provide another opportunity to connect those years of clinical information with what researchers observe in brain tissue.
A single donated brain can contribute to research questions that may not even have existed when the participant first joined a study.
Building a Clearer Picture of Alzheimer’s Disease
Alzheimer’s disease is extraordinarily complex. There is unlikely to be one gene, one cell type or one biological pathway that explains the entire disease.
Progress depends on building increasingly detailed pictures of what is happening in the brain and determining which changes are causes, which are consequences and which may represent opportunities for intervention.
This new brain atlas gives scientists an unusually detailed view of that landscape.
It will take time and additional research to understand which cellular changes ultimately matter most. But resources like this can help researchers ask better questions, test new hypotheses and move closer to understanding why Alzheimer’s disease develops, why some people remain more resilient than others and how the disease might one day be prevented or treated.
Learn more about participating in research at UCI MIND and how brain donation helps advance Alzheimer’s disease research.
Source: Nature, “Landmark map of human brain’s gene activity holds clues to Alzheimer’s disease and more,” September 23, 2026.
Read the Nature article
